期刊文献+

MMP-11在胃癌患者血清中的表达及临床意义 被引量:15

Expression of MMP-11 in serum of gastric cancer and its significance
下载PDF
导出
摘要 背景与目的:基质金属蛋白酶11(MMP-11)是基质金属蛋白酶家族中的一员,已有文献报道其与食管癌、肺癌等疾病的预后相关,尚缺乏MMP-11与胃癌的相关研究,本实验旨在观察基质金属蛋白酶11(MMP-11)在胃癌患者外周血清中的表达情况及临床意义。方法:收集2005年3月—2007年2月北京肿瘤医院收治的130例胃癌患者血清,采用逆转录-聚合酶链反应及酶联免疫技术检测MMP-11mRNA及蛋白表达情况。取20例正常健康人血清为对照组。结果:MMP-11mRNA在正常人群中表达的阳性率为5%,而在胃癌患者外周血清中阳性表达率(68.4%)高于正常人群;MMP-11蛋白在胃癌患者外周血清中表达量为(44±27)ng/ml,高于正常人群的(3±3)ng/ml;130例胃癌患者中,根治术后辅助治疗未见复发30例;术后复发或(和)转移的胃癌患者30例,复发、转移组血清MMP-11蛋白表达量(51±27)ng/ml,术后未见复发、转移的胃癌患者血清MMP-11蛋白表达量(27±28)ng/ml;两组患者外周血清MMP-11mRNA表达差异与蛋白水平一致。结论:MMP-11在胃癌患者外周血清中高表达,显著高于正常人群,尤其在根治术后转移和(或)复发的晚期患者的外周血中,推测其可能作为胃癌诊断、复发/转移的分子标志物。 Background and purpose: Matrix metalloproteinasel 1 ( MMP-11) is an interesting member of the MMP family, and its overexpression has been demonstrated in human cancers such as non-small cell lung cancer and oesophageal adenocarcinoma. Furthermore, strong MMP11 gene expression is correlated with both inereased aggressiveness of tumors and a poreclinieal outcome, but there was no related reports, on gastric cancer. We focussed our study cn the significance of MMP-11 expression in gastric cancer. Methods: MMP-11 was selected and confirmed at both mRNA and protein level in 130 cases of gaslrie cancer sennn specimen by RT-PCR, enzyme-linked-immuno-sorbent-assay (ELISA) lechniques, respectively. Results: The total positive rates of serum MMP-11 mRNA in gastric cancer and healthy people were 68.4vk and 5%. respectively. Our data demonstrated that MMP-11 protein levels in gastric cancer were (44 ± 27) ng/ml, significantly higher than those in control subjects ( P = 0. 001). MMP-11 protein levels in 30 cases with recurrencc were (51 ± 27) ng/ml and (27 ± 28)ng/ml in 30 patienls without reculTcnee. MMP-11mRNA positive expression was consistent with M MP-11 protein lexels iH gastric cancer patiellts. Conclusions: Serum MMP-11 nlay play an important role as a biomarker in diagnosis and prediction of recun'enl gastric cancer.
出处 《中国癌症杂志》 CAS CSCD 2007年第12期968-972,共5页 China Oncology
关键词 基质金属蛋白酶11 胃癌 转移 malrix metalloproteinase 11 : gastric cancer: metastasis
  • 相关文献

参考文献6

  • 1叶正宝,朱正纲.进展期胃癌综合治疗的现状和进展[J].中国癌症杂志,2006,16(10):771-774. 被引量:11
  • 2秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 3Annin C, Shiu K, Kwan L. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble Ecadherin[J]. Cancer,2005, 104(4) :740-746.
  • 4Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, et al. Overexpression of eathepsin f, matrix metalloproteinases 11 and 12 in cervical cancer[ J]. BMC cancer,2005,5( 1 ) :68.
  • 5Iida J,Wilhelmson K L,Priee M A, et al. Membrane Type-1 Matrix Metalloproteinase promotes human melanoma invasion and growth [ J ]. J Invest Dermatol, 2004,122 ( 1 ) : 167-176.
  • 6Soni S, Mathur M, Shukla NK, et al. Stromelysin-3 expression is an early event in human oral tumorigenesis [ J ]. Int J Cancer, 2003,107 (2) :309-316.

二级参考文献33

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40.
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328.
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a.
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a.
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281.
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235.
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020.

共引文献276

同被引文献209

引证文献15

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部